DSGN (Design Therapeutics) Notes Receivable: $0.00 Mil (As of Mar. 2026)


DSGN Design Therapeutics Inc DSGN
33 GF Score
Price $15.65
! 2 Warning Signs
View Full Analysis

What is Design Therapeutics Notes Receivable?

Design Therapeutics DSGN +6.68% 33 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates DSGN with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Design Therapeutics's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Design Therapeutics Notes Receivable Related Terms

Design Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Design Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Design Therapeutics Notes Receivable Chart

Design Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Design Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DSGN
33GF Score
Design Therapeutics Inc DSGN
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Design Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Design Therapeutics (DSGN) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Design Therapeutics and its competitors.
Is Design Therapeutics' Notes Receivable too high?
Design Therapeutics' current Notes Receivable is $0.00 Mil. Overall, Design Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Design Therapeutics' Notes Receivable compare to SPRY and GERN?
Design Therapeutics' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Design Therapeutics and its competitors. Design Therapeutics's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Design Therapeutics stock overvalued right now?
Design Therapeutics (DSGN) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Design Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Design Therapeutics (DSGN), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Design Therapeutics Business Description

Address 6005 Hidden Valley Road, Suite 110, Carlsbad, CA, USA, 92011
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
33GF Score

Get the complete analysis for DSGN

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.65
Price